Growth Metrics

Scholar Rock Holding (SRRK) Cash from Financing Activities (2017 - 2026)

Scholar Rock Holding's quarterly Cash from Financing Activities came in at $193.8 million in Q1 2026, up 4548.26% year-on-year from $4.2 million in Q1 2025, and up 164.42% quarter-over-quarter from $73.3 million in Q4 2025.

Scholar Rock Holding has reported Cash from Financing Activities for 10 years, with the latest figure at $193.8 million in Q1 2026.

  • For the quarter ending Q1 2026, Cash from Financing Activities rose 4548.26% year-over-year to $193.8 million; the trailing twelve-month figure through Mar 2026 stood at $418.0 million (up 19.2% YoY), and the FY2025 full-year result was $228.4 million, down 35.3% from the prior year.
  • Cash from Financing Activities for Q1 2026 stood at $193.8 million, up from $73.3 million in the prior quarter.
  • The five-year high for Cash from Financing Activities was $346.4 million in Q4 2024, with the low at -$970000.0 in Q4 2022.
  • Average Cash from Financing Activities over 5 years is $63.1 million, with a median of $4.7 million recorded in 2023.
  • Year-over-year, Cash from Financing Activities plunged 123.66% in 2022 and jumped 86929.52% in 2025.
  • Tracing SRRK's Cash from Financing Activities over 5 years: stood at -$970000.0 in 2022, then jumped by 10051.44% to $96.5 million in 2023, then surged by 258.82% to $346.4 million in 2024, then slumped by 78.84% to $73.3 million in 2025, then soared by 164.42% to $193.8 million in 2026.
  • The last three Cash from Financing Activities figures came in at $193.8 million (Q1 2026), $73.3 million (Q4 2025), and $144.5 million (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing Activities (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - 7.00 Mn
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -600,000.00
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - 53,000.00
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn -538.80 Mn
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn -802.20 Mn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 15.71 Mn
10 Scholar Rock Holding 500.61 Mn 20.67 Mn - 193.79 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 193.79 Mn
Mar 31, 2026 193.79 Mn
Dec 31, 2025 73.29 Mn
Dec 31, 2025 73.29 Mn
Sep 30, 2025 144.47 Mn
Sep 30, 2025 144.47 Mn
Jun 30, 2025 6.47 Mn
Jun 30, 2025 6.47 Mn
Mar 31, 2025 4.17 Mn
Mar 31, 2025 4.17 Mn
Dec 31, 2024 346.37 Mn
Dec 31, 2024 346.37 Mn
Sep 30, 2024 166,000.00
Sep 30, 2024 166,000.00
Jun 30, 2024 -33,000.00
Jun 30, 2024 -33,000.00
Mar 31, 2024 6.53 Mn
Mar 31, 2024 6.53 Mn
Dec 31, 2023 96.53 Mn
Dec 31, 2023 96.53 Mn
Sep 30, 2023 280,000.00
Sep 30, 2023 280,000.00
Jun 30, 2023 4.69 Mn
Jun 30, 2023 4.69 Mn
Mar 31, 2023 1.08 Mn
Mar 31, 2023 1.08 Mn
Dec 31, 2022 -970,000.00
Dec 31, 2022 -970,000.00
Sep 30, 2022 -451,000.00
Sep 30, 2022 -451,000.00
Jun 30, 2022 195.77 Mn
Jun 30, 2022 195.77 Mn
Mar 31, 2022 481,000.00
Mar 31, 2022 481,000.00
Dec 31, 2021 39.70 Mn
Dec 31, 2021 39.70 Mn
Sep 30, 2021 1.91 Mn
Sep 30, 2021 1.91 Mn
Jun 30, 2021 607,000.00
Jun 30, 2021 607,000.00
Mar 31, 2021 2.74 Mn
Mar 31, 2021 2.74 Mn
Dec 31, 2020 246.46 Mn
Dec 31, 2020 246.46 Mn
Sep 30, 2020 368,000.00
Sep 30, 2020 368,000.00
Jun 30, 2020 595,000.00
Jun 30, 2020 595,000.00
Mar 31, 2020 399,000.00
Mar 31, 2020 399,000.00
Dec 31, 2019 818,000.00
Dec 31, 2019 818,000.00
Sep 30, 2019 6.12 Mn
Sep 30, 2019 6.12 Mn
Jun 30, 2019 42.10 Mn
Jun 30, 2019 42.10 Mn
Mar 31, 2019 -157,000.00
Mar 31, 2019 -157,000.00
Dec 31, 2018 16.93 Mn
Dec 31, 2018 16.93 Mn
Sep 30, 2018 -1.46 Mn
Sep 30, 2018 -1.46 Mn
Jun 30, 2018 78.97 Mn
Jun 30, 2018 78.97 Mn
Mar 31, 2018 -167,000.00
Mar 31, 2018 -167,000.00
Dec 31, 2017 46.72 Mn
Dec 31, 2017 46.72 Mn
Sep 30, 2017 -167,000.00
Sep 30, 2017 -167,000.00